Transcending the proteomic ceiling: regulatory networks, translational barriers, and the AI-assisted opportunities of microRNA therapeutics

MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) that regulate gene expression post-transcriptionally, guiding Argonaute-containing RNA-Induced Silencing Complexes (RISC) to complementary messenger RNA (mRNA) sequences to repress translation and promote degradation. Because a single miRNA can influence hundreds of transcripts, these molecules offer access to regulatory nodes, including transcription factors and protein-protein interaction interfaces, that conventional antibodies and small-molecule inhibitors cannot reach, constrained as these are by target “druggability”. This has driven sustained interest in miRNA-driven therapeutics—mimics, antagomiRs, and antisense oligonucleotides—as a route to modulating disease networks directly at the RNA level. This narrative review synthesizes current understanding of miRNA biogenesis, delivery platforms such as lipid nanoparticle (LNP) encapsulation and chemically modified oligonucleotides, as well as miRNA dysregulation across oncological, cardiovascular, and renal pathologies. We also examine the clinical trajectory of representative candidates (Cobomarsen, Remlarsen, Miravirsen) and the roadblocks—off-target effects, delivery inefficiency, and immunogenicity—that have limited their translation. Finally, we review emerging machine learning (ML) and deep learning (DL) applications to miRNA target prediction and biomarker discovery, including tools that outperform established prediction algorithms, considering whether these computational approaches address, rather than merely reframe, the field’s translational bottlenecks. We conclude that miRNA therapeutics remain constrained by delivery and safety challenges, while artificial intelligence (AI)-assisted discovery represents a plausible, yet clinically unproven, avenue of progress.

Authors

Institutions

Publication Details

Journal
ExRNA
Published
2026-11-20
DOI
https://doi.org/10.55092/exrna20260017
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Transcending the proteomic ceiling: regulatory networks, translational barriers, and the AI-assisted opportunities of microRNA therapeutics

Kshitiz K, Venkatesh KM
ExRNA
MicroRNA in disease regulation
article

Transcending the proteomic ceiling: regulatory networks, translational barriers, and the AI-assisted opportunities of microRNA therapeutics

Kshitiz K, Venkatesh KM
article en

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) that regulate gene expression post-transcriptionally, guiding Argonaute-containing RNA-Induced Silencing Complexes (RISC) to complementary messenger RNA (mRNA) sequences to repress translation and promote degradation. Because a single miRNA can influence hundreds of transcripts, these molecules offer access to regulatory nodes, including transcription factors and protein-protein interaction interfaces, that conventional antibodies and small-molecule inhibitors cannot reach, constrained as these are by target “druggability”. This has driven sustained interest in miRNA-driven therapeutics—mimics, antagomiRs, and antisense oligonucleotides—as a route to modulating disease networks directly at the RNA level. This narrative review synthesizes current understanding of miRNA biogenesis, delivery platforms such as lipid nanoparticle (LNP) encapsulation and chemically modified oligonucleotides, as well as miRNA dysregulation across oncological, cardiovascular, and renal pathologies. We also examine the clinical trajectory of representative candidates (Cobomarsen, Remlarsen, Miravirsen) and the roadblocks—off-target effects, delivery inefficiency, and immunogenicity—that have limited their translation. Finally, we review emerging machine learning (ML) and deep learning (DL) applications to miRNA target prediction and biomarker discovery, including tools that outperform established prediction algorithms, considering whether these computational approaches address, rather than merely reframe, the field’s translational bottlenecks. We conclude that miRNA therapeutics remain constrained by delivery and safety challenges, while artificial intelligence (AI)-assisted discovery represents a plausible, yet clinically unproven, avenue of progress.

ExRNA
K S Hegde Medical Academy (IN)
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon